Removing barriers to global pandemic influenza vaccination

Gigi Gronvall, Luciana L. Borio

Research output: Contribution to journalReview article

Abstract

This article clarifies the regulatory issues surrounding influenza pandemic vaccine for the larger policy community and describes the need for regulatory harmonization. Vaccination would save lives in an influenza pandemic, but a lack of global manufacturing capacity will leave most of the world without access to vaccine. Capacity can be expanded if governments harmonize their regulatory policies. This article details the regulatory approaches taken by the United States, the European Union, and Japan for pandemic vaccine development, three regions that produce the majority of the world's seasonal influenza vaccine. They should quickly converge on regulatory requirements, intellectual property considerations, the use of recombinant DNA techniques for vaccine production, and technical issues about the composition of pandemic vaccine.

Original languageEnglish (US)
Pages (from-to)168-175
Number of pages8
JournalBiosecurity and Bioterrorism
Volume4
Issue number2
DOIs
StatePublished - Jul 24 2006
Externally publishedYes

Fingerprint

influenza
Vaccines
vaccination
vaccine
Pandemics
Human Influenza
contagious disease
Vaccination
Influenza Vaccines
regulatory policy
harmonization
intellectual property
Intellectual Property
DNA Vaccines
manufacturing
European Union
Japan
regulatory approach
lack
Intellectual property

ASJC Scopus subject areas

  • Health(social science)
  • Public Health, Environmental and Occupational Health
  • Management, Monitoring, Policy and Law

Cite this

Removing barriers to global pandemic influenza vaccination. / Gronvall, Gigi; Borio, Luciana L.

In: Biosecurity and Bioterrorism, Vol. 4, No. 2, 24.07.2006, p. 168-175.

Research output: Contribution to journalReview article

@article{3a631c186f1a4b2e94ade1ea7e5ad85f,
title = "Removing barriers to global pandemic influenza vaccination",
abstract = "This article clarifies the regulatory issues surrounding influenza pandemic vaccine for the larger policy community and describes the need for regulatory harmonization. Vaccination would save lives in an influenza pandemic, but a lack of global manufacturing capacity will leave most of the world without access to vaccine. Capacity can be expanded if governments harmonize their regulatory policies. This article details the regulatory approaches taken by the United States, the European Union, and Japan for pandemic vaccine development, three regions that produce the majority of the world's seasonal influenza vaccine. They should quickly converge on regulatory requirements, intellectual property considerations, the use of recombinant DNA techniques for vaccine production, and technical issues about the composition of pandemic vaccine.",
author = "Gigi Gronvall and Borio, {Luciana L.}",
year = "2006",
month = "7",
day = "24",
doi = "10.1089/bsp.2006.4.168",
language = "English (US)",
volume = "4",
pages = "168--175",
journal = "Health security",
issn = "2326-5094",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Removing barriers to global pandemic influenza vaccination

AU - Gronvall, Gigi

AU - Borio, Luciana L.

PY - 2006/7/24

Y1 - 2006/7/24

N2 - This article clarifies the regulatory issues surrounding influenza pandemic vaccine for the larger policy community and describes the need for regulatory harmonization. Vaccination would save lives in an influenza pandemic, but a lack of global manufacturing capacity will leave most of the world without access to vaccine. Capacity can be expanded if governments harmonize their regulatory policies. This article details the regulatory approaches taken by the United States, the European Union, and Japan for pandemic vaccine development, three regions that produce the majority of the world's seasonal influenza vaccine. They should quickly converge on regulatory requirements, intellectual property considerations, the use of recombinant DNA techniques for vaccine production, and technical issues about the composition of pandemic vaccine.

AB - This article clarifies the regulatory issues surrounding influenza pandemic vaccine for the larger policy community and describes the need for regulatory harmonization. Vaccination would save lives in an influenza pandemic, but a lack of global manufacturing capacity will leave most of the world without access to vaccine. Capacity can be expanded if governments harmonize their regulatory policies. This article details the regulatory approaches taken by the United States, the European Union, and Japan for pandemic vaccine development, three regions that produce the majority of the world's seasonal influenza vaccine. They should quickly converge on regulatory requirements, intellectual property considerations, the use of recombinant DNA techniques for vaccine production, and technical issues about the composition of pandemic vaccine.

UR - http://www.scopus.com/inward/record.url?scp=33746078819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746078819&partnerID=8YFLogxK

U2 - 10.1089/bsp.2006.4.168

DO - 10.1089/bsp.2006.4.168

M3 - Review article

C2 - 16792484

AN - SCOPUS:33746078819

VL - 4

SP - 168

EP - 175

JO - Health security

JF - Health security

SN - 2326-5094

IS - 2

ER -